The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

被引:24
|
作者
Anonychuk, Andrea [1 ,2 ,3 ]
Woo, Gloria [4 ]
Vyse, Andrew [1 ]
Demarteau, Nadia [1 ]
Tricco, Andrea C. [5 ]
机构
[1] GlaxoSmithKline Vaccines, Wavre, Belgium
[2] Abbott Labs, Div Diagnost, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Div Diagnost, Mississauga, ON L5N 3R3, Canada
[4] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
关键词
NEISSERIA-MENINGITIDIS; CONJUGATE VACCINE; UNITED-STATES; SEROGROUP; IMMUNOGENICITY; POLYSACCHARIDE; SAFETY; W-135; INFECTION; ENGLAND;
D O I
10.1007/s40273-013-0057-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Invasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases. Objective To systematically review the literature on the costs and public health burden associated with IMD outbreaks. Methods Studies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community). Results Sixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222. Conclusion IMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
引用
收藏
页码:563 / 576
页数:14
相关论文
共 50 条
  • [41] Review of the epidemiology, diagnosis and management of invasive meningococcal disease in Vietnam
    Nguyen, Phung Nguyen The
    Hung, Nguyen Thanh
    Mathur, Gaurav
    Pinto, Thatiana de Jesus Pereira
    Minh, Nguyen Hoan Le
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [42] Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex
    Stoof, Susanne P.
    Rodenburg, Gerwin D.
    Knol, Mirjam J.
    Ruemke, Lidewij W.
    Bovenkerk, Sandra
    Berbers, Guy A. M.
    Spanjaard, Lodewijk
    van der Ende, Arie
    Sanders, Elisabeth A. M.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (08) : 1281 - 1292
  • [43] A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions
    Digieri Chicuto, Luciana Andrea
    de Moraes, Camile
    de Moraes, Jose Cassio
    Safadi, Marco Aurelio P.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (08) : 1945 - 1950
  • [44] Tracking a serial killer: Integrating phylogenetic relationships, epidemiology, and geography for two invasive meningococcal disease outbreaks
    Ezeoke, Ifeoma
    Galac, Madeline R.
    Lin, Ying
    Liem, Alvin T.
    Roth, Pierce A.
    Kilianski, Andrew
    Gibbons, Henry S.
    Bloch, Danielle
    Kornblum, John
    Del Rosso, Paula
    Janies, Daniel A.
    Weiss, Don
    PLOS ONE, 2018, 13 (11):
  • [45] Global epidemiology of serogroup Y invasive meningococcal disease: a literature review
    Htar, Myint Tin Tin
    Findlow, Jamie
    Balmer, Paul
    Swerdlow, David
    EPIDEMIOLOGY & INFECTION, 2024, 152 : e157
  • [46] A review of the epidemiology of invasive meningococcal disease and vaccination strategies in North Africa
    Taha, Muhamed-Kheir
    Presa, Jessica
    Serra, Lidia
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 104 : 189 - 197
  • [47] Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
    Izurieta, Patricia
    Bahety, Priti
    Adegbola, Richard
    Clarke, Christopher
    Hoet, Bernard
    EXPERT REVIEW OF VACCINES, 2018, 17 (06) : 479 - 493
  • [48] Review of invasive meningococcal disease during the last 40 years in Turkey
    Bakir, Mustafa
    Altinel, Serdar
    EXPERT REVIEW OF VACCINES, 2015, 14 (08) : 1089 - 1097
  • [49] A systematic review of the diagnostic accuracy of Loop-mediated-isothermal AMPlification (LAMP) in thediagnosis of invasive meningococcal disease in children
    Waterfield, Thomas
    Fairley, Derek
    Blackwood, Bronagh
    McKenna, James
    Shields, Michael D.
    BMC PEDIATRICS, 2019, 19 (1)
  • [50] Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database
    Huang, Liping
    Heuer, Olivia Denise
    Janssen, Sabrina
    Haeckl, Dennis
    Schmedt, Niklas
    PLOS ONE, 2020, 15 (01):